Planning Before the Test Line

A bipolar diagnosis does not decide whether you should become a parent. It does make early planning useful. The goal is to protect your health and your baby’s health together, with honest attention to both illness and treatment risks. No choice removes every risk, and a medication-free pregnancy is not by itself a risk-free pregnancy.

If you are planning pregnancy, arrange a visit with the prescribing and obstetric teams before conception when possible. If you already have a positive test, contact both promptly, especially if you take valproate. Do not abruptly stop psychiatric medication solely because the test is positive. ACOG guidance supports tailored care that weighs recurrence alongside exposure.1

Key takeaways

• A bipolar diagnosis does not decide whether you become a parent; it makes a preconception visit with both the prescribing and obstetric teams worth arranging early.
• A medication-free pregnancy is not by itself a risk-free pregnancy, because recurrence carries its own risks; valproate deserves a direct, early review, and a positive test is not an instruction to stop on your own.
• Plan the weeks after birth as carefully as the pregnancy: who reviews you, how fast you can reach them, and who covers the infant if urgent assessment is needed.

Zoom

Planning creates choices

A preconception visit can review what has kept you well, what has caused problems, and what support will be available. It can also address contraception while a plan is being made. You can ask these questions before you know whether or when you want to become pregnant.

Think of the handoffs arranged before a major stage production: people need to know their roles and whom to call when something changes. That is the useful part of the image. Pregnancy and postpartum are not predictable performances, and a careful plan cannot control every event.

Start with your actual history. Have you had depression, mania, mixed symptoms, or psychosis? What happened during earlier treatment changes or after a previous birth? Which medicine clearly helped, and what happened when it was tried differently? These details are more useful than sorting medicines into a simple safe or unsafe column.

The plan should include practical limits. Can you get to labs? Who covers the prescribing clinician’s absence? Is there someone who can help overnight? Can the psychiatric and obstetric teams share information with your consent? A plan that depends on resources you cannot reach needs revision.

The comparison includes illness

Pregnancy studies often compare people who take a medicine with people who do not. Those groups may differ in illness severity, prior episodes, other health conditions, and reasons for treatment. An association with an outcome does not prove that the medicine caused it.

Recurrence can affect sleep, nutrition, judgment, safety, relationships, and access to prenatal care. In a prospective study of people well at conception, stopping mood-stabilizing treatment was associated with more recurrence during pregnancy. The study was observational, so it cannot assign one person’s future risk or prove that every continuation choice is best. Viguera and colleagues examined this difficult balance.2

The relevant question is not only “Could this medicine affect a fetus?” It is also “What might happen if my illness returns, and what alternatives are realistic for me?” A team should be willing to discuss both directions without making you defend your wish for treatment or your concerns about exposure.

Valproate deserves an early, direct review

Valproate is treated differently because of established risks of major birth defects and adverse brain-development outcomes after pregnancy exposure. Some effects can arise very early, before pregnancy is recognized. ACOG recommends avoiding valproate during pregnancy when alternatives can be used. U.S. labeling restricts its use for bipolar disorder during pregnancy to conditions in which other treatments have failed or are unacceptable.

That makes preconception planning especially valuable. Discuss alternatives, the risk of recurrence during a change, and effective contraception while decisions are being made. These are U.S. treatment and labeling reviews; restrictions used in another country should not be described as California law. The current U.S. valproate label defines the warnings.3

If you have a positive test while taking valproate, contact your prescriber and obstetric team promptly and explain the medicine and timing. Ask for an urgent coordinated review. The warning is not an instruction to stop on your own and wait for the next appointment. A rushed change without a plan can create another problem.

Serious medication reactions still require their drug-specific urgent action. If lithium toxicity is suspected, stop/withhold lithium and obtain urgent medical help. Pregnancy does not cancel those instructions. The distinction is between an emergency reaction and a planned response to a new pregnancy.

Lithium requires modern numbers and context

Lithium is not by itself ruled out in pregnancy. It may be valuable for someone whose illness has responded well to it. It also has exposure risks that deserve a careful discussion using current evidence, rather than the much larger estimates circulated decades ago.

One large U.S. study examined cardiac malformations among live births after first-trimester exposure. The observed comparison was:

These are rounded observed study rates, not your baby’s predicted risk. The original counts were 16 among 663 lithium-exposed births and 15,251 among 1,322,955 unexposed births. Adjustment for measured differences still suggested increased risk, with uncertainty. The study included live births and could not eliminate all differences between groups. Patorno’s original study supports the comparison.4

Newer evidence adds questions rather than closing the case. A July 2026 Australian cohort associated lithium exposure during pregnancy with spontaneous preterm birth and cardiac outcomes. Its exposure window and population differed from the U.S. study, and other differences between groups may still affect the results. Those findings belong in shared review; the two studies should not be combined into a single personal percentage. The 2026 cohort makes those limits relevant.5

If lithium is continued, the team should plan maternal monitoring, fetal assessment when indicated, and coordination around delivery. Pregnancy and postpartum can alter lithium handling. Do not create your own dose change, labor hold, or restart plan from a general article.

Lamotrigine and antipsychotics need individual discussions

Lamotrigine may be an option when depressive episodes and maintenance are central concerns. Pregnancy can change how quickly the body clears it, and levels can rise again after birth. A small bipolar study documented large variation. It was not large enough to establish a universal adjustment plan or prove fetal safety. Clark and colleagues studied this monitoring issue.6

Tell the team about contraception changes too. Estrogen-containing products can change lamotrigine levels when started or stopped. Pregnancy planning should not leave one clinician changing hormones while another assumes exposure is unchanged. Drug-specific rash and interruption instructions still apply.7

Antipsychotics are not one uniform pregnancy option. Previous benefit, the drug, sedation, weight, and metabolic health matter. A large Swedish study found increased gestational-diabetes risk in a group that included olanzapine, quetiapine, and clozapine. It did not randomly compare each medicine or prove the same effect for each person. That cohort supports monitoring without a class-wide verdict.8

Ask what monitoring is already part of obstetric care and what your medicine adds. You should not have to interpret every result alone. The team should explain which symptoms or results require earlier contact and who will coordinate the next decision.

The plan must extend beyond delivery

The early postpartum period deserves explicit preparation because recurrence can occur after birth, including depression, mania, or psychosis. A review found substantial recurrence after birth, with different rates among medication-free and treated groups. These were not randomized groups, and the studies used different postpartum windows. A relapse estimate is not the same as a psychosis or hospital-admission estimate. Wesseloo’s original review and supporting work show why the timeframe matters.9

Before delivery, ask who will review you afterward and how rapidly you can reach them. The plan should not depend on recognizing an episode yourself while exhausted. With your consent, a chosen supporter can learn which changes require a call and where the plan is kept.

Include a backup for infant care if you need urgent assessment. This might involve a trusted adult taking over while another helps you reach care. It is a practical arrangement, not a prediction that you will become unwell or a reason to question your fitness as a parent.

Delivery instructions should be written by the treating teams. In one lithium monitoring cohort, levels changed across pregnancy and postpartum, but delivery itself did not cause an immediate uniform shift. A blanket “everyone must hold it in labor” rule misses that complexity. The original monitoring study supports individual coordination.10

Feeding and sleep belong in one conversation

Ask how feeding preferences, infant health, medication exposure, and your need for sleep can fit together. Overnight support may involve shifts, help with settling, expressed milk, formula, or another tailored arrangement. No feeding method measures your love or commitment.

Sleep protection is more than telling a new parent to rest. Who can take over an agreed task? What if the helper becomes ill? What if feeding is painful or the baby needs extra care? A realistic backup is more useful than a plan that requires every night to go perfectly.

Breastfeeding decisions need drug-specific advice. The current U.S. lithium Medication Guide advises against breastfeeding.13 LactMed describes selected conditions in which a healthy full-term infant may breastfeed with specialist assessment and monitoring. Those are different recommendations, and the disagreement should remain visible. Newborn age, prematurity, dehydration, illness, and access to infant testing can change the balance. LactMed’s June 2026 review does not promise universal safety.11

Lamotrigine has a different discussion. Contact the infant’s clinician promptly for poor feeding, unusual drowsiness, or rash. Breathing difficulty needs emergency help. If an infant rash develops during lamotrigine exposure through breast milk, interrupt breastfeeding until the cause is assessed, as LactMed advises. Seek prompt guidance on feeding the infant and do not independently stop the parent’s medicine. The parent’s postpartum treatment also needs review. Much available evidence comes from epilepsy care. LactMed’s March 2026 review supports tailored monitoring rather than a blanket rule for all medicines.12

Two ways to open the conversation

Hypothetical planning conversation: “I am thinking about pregnancy. I want to review which parts of treatment protect me, what exposure concerns matter, and who will coordinate care before and after birth.”

Hypothetical unplanned-pregnancy conversation: “I have a positive pregnancy test. These are the medicines I take, and this is when I last took them. I need timely advice from my psychiatric and obstetric teams before I make changes.”

If you cannot reach the usual clinician, use the practice’s covering route or an urgent service for timely assessment. Tell the team about insurance, transport, language, or appointment barriers. A referral needs an access plan, not merely a name.

Put names next to the tasks

A plan becomes easier to use when each task has a person attached to it. Who books the next visit? Who checks that the lab request arrived? Who can help with a meal or a ride? If the answer is “no one yet,” tell the team. A blank space shows a need for help, not a failure to prepare.

Ask for a copy that is short enough to use when tired. Keep the longer drug and birth instructions with it. If your plans change, update the people who need to know. You may change your mind about feeding, support, or who attends visits. Those choices can be discussed as part of care.

If you feel blamed for needing treatment, say so when you can. The aim is to weigh real choices with you. Your health is part of the baby’s care, and your questions about either side deserve a clear answer.

Changes after birth that should not wait

Brief tearfulness and emotional shifts after birth are often called baby blues. Persistent depression, major loss of function, or symptoms that concern you still deserve assessment. Severe sleep loss can also be both a strain and part of a developing illness. Feeling unusually energized despite little sleep is different from being tired because infant care kept you awake.

Contact care today for rising activation, severe anxiety or depression, rapidly changing sleep need, or difficulty caring for yourself. New psychosis or severe confusion after birth requires emergency assessment. Do not treat it as ordinary stress or something to sleep off. Call 911 for immediate medical or physical danger. Have a safe adult care for the infant if you are too unwell to do so, while help is arranged. Calling or texting 988 (the Suicide & Crisis Lifeline) can help when the next step is uncertain.14

This week, identify who will coordinate the psychiatric and obstetric plan, and book that conversation when feasible.

Frequently asked questions

Should I stop medication before trying?

Do not make a planned stop without a coordinated review. The decision needs your episode history, prior benefit, the specific medicine, exposure concerns, and available alternatives. A preconception visit gives more time to consider changes and follow-up. Valproate deserves particular attention. Serious medication reactions remain an exception requiring the urgent action for that drug.

What if the test is already positive?

Contact the prescribing and obstetric teams promptly and give the exact medicine list and timing. Ask who will coordinate the review and how to reach covering care if needed. A positive test alone is not an instruction to abruptly discontinue treatment. If you are acutely unwell or have a serious reaction, seek urgent medical assessment.

Why is valproate treated differently?

It has established congenital and neurodevelopmental risks, including effects from early pregnancy exposure. U.S. labeling and professional guidance therefore give it special priority in reproductive planning. That supports reviewing alternatives before conception when possible. If pregnancy has already occurred, the response is urgent coordinated advice, not a self-directed stop or a promise that exposure determines the outcome.

Is lithium always ruled out?

No. For some people, its previous benefit and recurrence risks may support continued use with careful monitoring. Exposure risks still require discussion, including cardiac and other pregnancy outcomes. Study averages cannot predict one baby’s outcome. The plan should include psychiatric, obstetric, delivery, and postpartum coordination rather than a general safe or unsafe label.

How can breastfeeding and sleep be planned together?

Discuss feeding preferences, the exact medicine, infant age and health, monitoring, and practical overnight help in the same visit. A workable plan may include different forms of feeding or shared tasks. Lithium guidance differs between its U.S. guide and LactMed’s selected monitored circumstances. The choice needs a joint team discussion, not a test of parental commitment.

Which postpartum changes are an emergency?

New psychosis, severe confusion, immediate self-harm danger, or inability to keep the parent or infant safe needs emergency assessment. Call 911 for immediate danger. Do not wait for routine follow-up or assume sleep alone will resolve it. Marked activation, severe depression, or rapidly changing sleep need also warrants prompt clinical contact before the situation escalates.

This article is for education, not personal medical advice. Do not start, stop, restart, or change a medication without the clinician who manages it. Every PubMed citation, crisis number, and internal link in this article was verified against its primary source on September 8, 2026. Guidelines, drug labels, and public-health data change; confirm current status before acting on anything here.

Related reading on NP FADY

• Postpartum Depression Doesn’t Always Look Like Sadness
• Bipolar Disorder in Women: Why Hormonal Changes Make a Difference
• The Level Is a Conversation, Not a Grade
• Written in Calm Weather
• The Bridge You Don’t Notice
• Mood Stabilizers Demystified: Lithium, Lamictal, and Beyond

References

1. ACOG. Treatment and Management of Mental Health Conditions During Pregnancy and Postpartum: Clinical Practice Guideline No. 5. Obstetrics & Gynecology. 2023;141:1262–1288. doi:10.1097/AOG.0000000000005202. Full reprint.

2. Viguera AC, et al. Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation. American Journal of Psychiatry. 2007;164:1817–1824. doi:10.1176/appi.ajp.2007.06101639. Original record.

3. AbbVie. DEPAKOTE ER prescribing information. Revised March 2026. Current label.

4. Patorno E, et al. Lithium use in pregnancy and the risk of cardiac malformations. New England Journal of Medicine. 2017;376:2245–2254. doi:10.1056/NEJMoa1612222. Original report.

5. Roddy Mitchell A, et al. Lithium Use in Pregnancy and the Risk of Spontaneous Preterm Birth: An Australian Statewide Retrospective Cohort Study. BJOG. Published July 7, 2026. doi:10.1111/1471-0528.70301. Full original.

6. Clark CT, et al. Lamotrigine dosing for pregnant patients with bipolar disorder. American Journal of Psychiatry. 2013;170:1240–1247. doi:10.1176/appi.ajp.2013.13010006. Original report.

7. GSK. LAMICTAL prescribing information. October 2025. Current label.

8. Heinonen E, et al. Antipsychotic Use During Pregnancy and Risk for Gestational Diabetes: A National Register-Based Cohort Study in Sweden. CNS Drugs. 2022;36:529–539. doi:10.1007/s40263-022-00908-2. Full original.

9. Wesseloo R, et al. Risk of postpartum relapse in bipolar disorder and postpartum psychosis: a systematic review and meta-analysis. American Journal of Psychiatry. 2016;173:117–127. doi:10.1176/appi.ajp.2015.15010124. Original work in thesis.

10. Wesseloo R, et al. Lithium dosing strategies during pregnancy and the postpartum period. British Journal of Psychiatry. 2017;211:31–36. doi:10.1192/bjp.bp.116.192799. Original report.

11. NLM LactMed. Lithium. Updated June 15, 2026. Current review.

12. NLM LactMed. Lamotrigine. Updated March 15, 2026. Current review.

13. PAI Pharma. Lithium Medication Guide. January 2025. U.S. guide.

14. Suicide & Crisis Lifeline. Get help. Accessed 2026-09-08. Official support route.

If you or someone you know is in crisis

• Call 911 or go to your nearest emergency room for any life-threatening emergency.
• 988 Suicide & Crisis Lifeline — call or text 988, available 24/7. En español: marque 988 y oprima 2. Veterans: 988 and press 1, or text 838255.
• Crisis Text Line — text HOME to 741741.
• The Trevor Project (crisis support for LGBTQ+ young people) — call 1-866-488-7386, or text START to 678-678.
• National Sexual Assault Hotline (RAINN) — call 1-800-656-HOPE (4673) or text HOPE to 64673; free, confidential, 24/7. Online chat at RAINN.org/hotline.
• National Domestic Violence Hotline — call 1-800-799-SAFE (7233) or text START to 88788; 24/7, help in 200+ languages. Online chat at TheHotline.org. If your phone or computer may be monitored, calling from a safer device is an option.
• Riverside County — Inland SoCal Crisis Helpline 951-686-HELP (4357), 24/7 (Inland SoCal United Way / 211+, in partnership with RUHS-BH); Community Access, Referral, Evaluation and Support (CARES) Line 800-499-3008, 24/7.
• San Bernardino County — Access Unit (Behavioral Health Helpline) 888-743-1478, 24/7; Mobile Crisis/CCRT 800-398-0018 (24/7, all ages) or text 909-420-0560. Arrowhead Regional Medical Center (ARMC) has a dedicated walk-in adolescent psychiatric ER (ages 13–17).
• Children under 13 — call 911 for immediate danger, contact your county's mobile crisis team (they respond to all ages), or go to the nearest pediatric emergency room.
• California Peer-Run Warm Line (non-crisis — someone to talk to) — call or text 1-855-600-WARM (9276); daytime and evening hours, not a 24/7 line.
• NP Fady (non-emergency) — for routine scheduling or questions, call (909) 707-6261. This line is not monitored for emergencies.